News Agency

Menarini Group Presents New and Expanded Data at the 2024 San Antonio Breast Cancer Symposium Reinforcing the Role of ORSERDU® (Elacestrant) for Patients with ER+, HER2- Advanced or Metastatic Breast Cancer (mBC)

  • Written by PR Newswire
Menarini Group Presents New and Expanded Data at the 2024 San Antonio Breast Cancer Symposium Reinforcing the Role of ORSERDU® (Elacestrant) for Patients with ER+, HER2- Advanced or Metastatic Breast Cancer (mBC)
  • Real-world evidence bolsters the efficacy of ORSERDU for the treatment of patients with ER+/HER2- ESR1-mut advanced or mBC.
  • Updated results of elacestrant in combination with abemaciclib show favorable efficacy regardless of the ESR1 mutation status, with a manageable and predictable safety profile in patients with ER+/HER2- mBC.

FLORENCE,...

Read more: Menarini Group Presents New and Expanded Data at the 2024 San Antonio Breast Cancer Symposium...

Last-Mile Delivery Tracking: Ensuring Efficiency and Customer Satisfaction

As our lives increasingly revolve around the internet, especially with the current boom in eCommerce, it’s no surprise that customer expectations have become more demanding. Consumers now expect their goods to be delivered as quickly as possible, with a smooth... Read more

Writers Wanted



NewsServices.com

Content & Technology Connecting Global Audiences

More Information - Less Opinion